368 related articles for article (PubMed ID: 12602066)
1. Perspectives. CMS and Wall Street report...
Med Health; 2003 Jan; 57(4):7-8. PubMed ID: 12602066
[No Abstract] [Full Text] [Related]
2. Forecasting the future.
Tecnologica; 1999 Dec; ():1, 3-6, 14-5. PubMed ID: 10848110
[No Abstract] [Full Text] [Related]
3. Generics battle brand names over mortality of drug patents.
Betz R
J Healthc Resour Manag; 1995 Jul; 13(7):35-7. PubMed ID: 10144008
[No Abstract] [Full Text] [Related]
4. Drug costs threaten patent protection.
Cimons M
Nat Med; 2003 Jan; 9(1):9. PubMed ID: 12514706
[No Abstract] [Full Text] [Related]
5. Handle with care.
Macilwain C
Nature; 2006 Apr; 440(7087):990-1. PubMed ID: 16625170
[No Abstract] [Full Text] [Related]
6. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950
[TBL] [Abstract][Full Text] [Related]
7. Bills target biosimilar drugs.
Wadman M
Nature; 2009 Mar; 458(7237):394-5. PubMed ID: 19325595
[No Abstract] [Full Text] [Related]
8. SuperGenerics: a better alternative for biogenerics.
Charles SA
Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
[No Abstract] [Full Text] [Related]
9. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
10. Branded drug reformulation: the next brand vs. generic antitrust battleground.
Amoresano GV
Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
[No Abstract] [Full Text] [Related]
11. Pharmaceutical patent settlements: the antitrust risks.
Balto DA
Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
[No Abstract] [Full Text] [Related]
12. A generic problem.
Hanauer SB
Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
[No Abstract] [Full Text] [Related]
13. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
Dinh TQ
Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
[No Abstract] [Full Text] [Related]
14. Pharmaceuticals and medical devices: cost savings. Issue brief.
Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-33. PubMed ID: 23297446
[No Abstract] [Full Text] [Related]
15. Prescription drug pushers. Patents and ads are the big reasons pills are priced like perfume and caviar.
Sherrid P
US News World Rep; 2000 Oct; 129(17):40-2. PubMed ID: 11184929
[No Abstract] [Full Text] [Related]
16. Lowering the cost of prescription drugs.
Jindal B
J La State Med Soc; 2003; 155(1):51. PubMed ID: 12656276
[No Abstract] [Full Text] [Related]
17. The generic drug approval process.
Rheinstein PH
Am Fam Physician; 1993 Dec; 48(8):1357-60. PubMed ID: 8249762
[No Abstract] [Full Text] [Related]
18. Sword or shield? An overview and competitive analysis of the marketing of "authorized generics".
Zain S
Food Drug Law J; 2007; 62(4):739-77. PubMed ID: 18557229
[No Abstract] [Full Text] [Related]
19. Special patent provisions for pharmaceuticals: have they outlived their usefulness? A political, legislative and legal history of U.S. law and observations for the future.
Engelberg AB
Spec Law Dig Health Care Law; 2000 Sep; (258):9-48. PubMed ID: 11184791
[No Abstract] [Full Text] [Related]
20. Brand-name drug manufacturers risk antitrust violations by slowing generic production through patent layering.
Paine CS
Seton Hall Law Rev; 2003; 33(2):479-510. PubMed ID: 12715807
[No Abstract] [Full Text] [Related]
[Next] [New Search]
